Scarica l'app Stockscreener
117.25
0.51%
0.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers - The AI Journal
Incyte to present Phase 1 cancer data at ESMO Congress - Investing.com
Incyte stock hits 52-week high at 118.98 USD - Investing.com
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte CMO Steven Stein sells $3.19m in company stock - Investing.com
Lobbying Update: $110,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Form 4 Incyte Corporation For: 16 July By Investing.com - Investing.com Canada
Incyte (INCY) R&D chief withholds 22,919 shares to cover taxes - Stock Titan
Incyte CMO Steven Stein sells $3.19m in company stock By Investing.com - Investing.com UK
Incyte Corp (NASDAQ: INCY) EVP reports 1,949-share RSU tax withholding - Stock Titan
Incyte Corp (NASDAQ: INCY) PAO reports 1,790 shares withheld for RSU taxes - Stock Titan
What to Expect From Incyte's Q2 2026 Earnings Report - Barchart.com
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on VWD drug data - Investing.com
H.C. Wainwright reiterates Incyte stock rating on VWD drug data By Investing.com - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (INCY) Reveals Promising Data for New Treatment in Von Wi - GuruFocus
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3 - Yahoo Finance
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types - BioBuzz
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis - Yahoo Finance
INCY Maintained by BMO Capital -- Price Target Raised to $112 - GuruFocus
BMO raises Incyte stock price target to $112 on Opzelura strength By Investing.com - Investing.com South Africa
BMO raises Incyte stock price target to $112 on Opzelura strength - Investing.com Australia
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disord - Benzinga
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks - Yahoo Finance
Incyte reports 81% bleeding reduction in VWD study - grafa.com
Incyte reports phase 1/2 trial results for bleeding disorder drug By Investing.com - Investing.com South Africa
Incyte reports phase 1/2 trial results for bleeding disorder drug - Investing.com
Incyte stock holds steady as pipeline progress supports long-term growth outlook - Ad-hoc-news.de
Funds slated to go to Incyte will bankroll corridor improvement program - Delaware Business Now
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Forte, First Tracks soar on CD122 success in vitiligo; celiac next - BioWorld News
Incyte stock steadies on its oncology franchise - ad-hoc-news.de
2 Fast-Growing Pharmaceutical Stocks to Buy Now - Yahoo Finance
Incyte (INCY) Set to Release Q2 2026 Earnings with Positive Mark - GuruFocus
Incyte stock hits 52-week high at 118.77 USD - Investing.com
Incyte stock hits 52-week high at 118.77 USD By Investing.com - Investing.com UK
Incyte to Report Second Quarter 2026 Financial Results - BioSpace
Incyte to Report Second Quarter Financial Results - Business Wire
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Form 4 Incyte Corporation For: 7 July By Investing.com - Investing.com Canada
INCYTE (INCY) CEO’s RSU tax withholding adjusts reported share holdings - Stock Titan
INCYTE (INCY) CMO has 2,177 shares withheld to cover equity award taxes - Stock Titan
INCY Maintained by RBC Capital -- Price Target Raised to $99.00 - GuruFocus
Incyte Corporation (INCY) Completes Acquisition of Vega Therapeu - GuruFocus
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (INCY) Completes Acquisition of Vega Therapeutics - GuruFocus
Incyte completes $1.25B acquisition of Vega Therapeutics - grafa.com
Incyte completes $1.25B Vega Therapeutics acquisition By Investing.com - Investing.com South Africa
Incyte completes $1.25B Vega Therapeutics acquisition - Investing.com
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio - Business Wire
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion - Yahoo Finance
Truist Financial Maintains Incyte(INCY.US) With Hold Rating - Moomoo
INCYTE (INCY) director Paul J. Clancy receives 252-share fully vested stock grant - Stock Titan
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales - Insider Monkey
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):